EP1207854A1 - Liposomes conserves - Google Patents
Liposomes conservesInfo
- Publication number
- EP1207854A1 EP1207854A1 EP00959298A EP00959298A EP1207854A1 EP 1207854 A1 EP1207854 A1 EP 1207854A1 EP 00959298 A EP00959298 A EP 00959298A EP 00959298 A EP00959298 A EP 00959298A EP 1207854 A1 EP1207854 A1 EP 1207854A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- amount
- preserved
- cosmetic composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to the preservation of liposomal preparations against microbial contamination. More particularly, the present invention relates to a cosmetic liposomal preparations containing active ingredients which have previously been difficult to preserve, such as magnesium ascorbyl phosphate.
- Liposomes are spherical vesicles composed of lipid bilayers. Active ingredients inside the liposomes can be delivered to the skin by topical application of the liposomes.
- a general reference for the application of liposomes to cosmetics is Hayward, J.A. and Smith, W.P. Potential Applications of Liposomes in Cosmetic Science, in Cosmetic and Toiletries, 105:47-54, 1990.
- U.S. Pat. No. 5,585,109 to Hayward et al. teaches the cosmetic delivery of un-neutralized salicylic acid by a liposome formulation including a preservative.
- Liposome formulations are typically difficult to preserve against microbiological contamination.
- An 8-week challenge study is considered a standard measure of preservative efficacy within the cosmetic industry. All percentages given in the specification are percent by weight of the total composition weight, unless otherwise noted.
- a preserved cosmetic composition comprising: a) a vesicle-forming amount of lipids known to form, either alone or in combination, unilamellar vesicles; b) a cosmetic-effective amount of an active ingredient; c) a preservative-effective amount of a combination of sorbic acid and salicylic acid or water-soluble salts thereof; d) a base in an amount which provides a pH of about 5 to about 6 to the composition; and e) water.
- the cosmetic liposomes of the invention can optionally contain other ingredients conventionally employed in cosmetic products.
- ingredients include, but are not limited to, perfumes, colorants such as staining dyes and pigments, humectants, anti- dandruff agents, anti-acne agents, germicides, sunscreens, emollients, vitamins, sterols and other lipids.
- Preferred lipids include the synthetic or natural phospholipids, phosphatidylthanolamines, phosphatidylserines, cereamides, cerebrosides, phophatidylglycerides and non-ionic surfactants.
- Particularly preferred lipids are natural phospholipids such as soya lecithin, in an amount of 0.5 to 10%.
- Most preferred are natural phospholipids which have been substantially purified to increase the phosphatidylcholine content.
- Preferred active ingredients include any ingredient known for cosmetic use through topical application.
- active ingredients for use in the cosmetic liposomes of the invention include, but are not limited to, vitamins, herbal extracts, enzymes, growth factors, anti-dandruff agents, anti-acne agents, germicides and sterols.
- a "cosmetic-effective amount" of an active ingredient is that amount which is required in a liposome preparation for the active ingredient to have a discernible cosmetic effect upon topical application.
- a "preservative-effective amount" of a combination of sorbic acid and salicylic acid or water-soluble salts thereof is at least 0.1% of sorbic acid or a water-soluble salt of sorbic acid in combination with at least 0.1% of salicylic acid or a water-soluble salt of salicylic acid.
- sorbic acid is present in an amount from 0.1% to 5%
- salicylic acid or its water-soluble salt are present in an amount from 0.1% to 10%.
- the base used may be either organic or inorganic.
- a liposome composition of the cosmetic active ingredient magnesium ascorbyl phosphate is preserved by the addition of sorbic acid and salicylic acid.
- Previously known preservative systems were unsuccessful in preserving liposome compositions of magnesium ascorbyl phosphate.
- Magnesium ascorbyl phosphate functions to deliver a stabilized form of Vitamin C (ascorbic acid) to the skin.
- the stabilized Vitamin C functions as an antioxidant, skin tightener and pigment promoter.
- EXAMPLE 1 Mg Ascorbyl Phosphate Liposomes Preserved with 0.2% Salicylic Acid and 0.2% Sorbic Acid
- the sorbic acid and the salicylic acid were dissolved in water.
- the pH was then adjusted to a pH of 5.5 using the base.
- the active ingredient, Mg ascorbyl phosphate, was then added.
- the lecithin is added under agitation, and the mixture is processed by high shear homogenization or microfulidization until a particle size of between 100 nm and 300 nm is reached.
- the particle size was monitored by a Horiba LA-90 particle size analyzer (Horiba Instruments, Inc., Irvine, California).
- Mg ascorbyl phosphate liposomes were also prepared using two prior art preservatives, Phenonip (Nipa-Hardwicke, Inc., Wilmington, Deleware), and the combination of Dowicil (Dow Chemical USA, Midland, Michigan), methyl paraben and propyl paraben.
- Phenonip Napa-Hardwicke, Inc., Wilmington, Deleware
- Dowicil Dowicil
- the Phenonip was dissolved in water.
- the lecithin is added under agitation, and the mixture is processed by high shear homogenization or microfiilidization until a particle size of between 100 nm and 300 nm is reached.
- the particle size was monitored by a Horiba LA-90 particle size analyzer.
- the Dowicil 200, methyl paraben and propyl paraben were dissolved in water.
- the active ingredient, Mg ascorbyl phosphate, was then added.
- the lecithin is added under agitation, and the mixture is processed by high shear homogenization or microfiilidization until a particle size of between 100 nm and 300 nm is reached.
- the particle size was monitored by a Horiba LA-90 particle size analyzer.
- Comparative Example 2 were each inoculated with standardized cultures to provide a final concentration of 5.0 x 10 5 gram positive bacteria per gram, 5.0 x 10 5 gram negative bacteria per gram, 5.0 x 10 5 yeast per gram and 5.0 x 10 4 mold spores per gram.
- the inoculum was distributed uniformly throughout the preserved samples in a manner which minimized aeration. The samples were then stored at room temperature for the duration of the eight week study.
- each sample was taken one week after the first inoculation and every week thereafter until the eighth week.
- Each portion was diluted and plated on a series of petri dishes containing media which were selective for each of gram positive bacteria, gram negative bacteria, yeast and mold.
- the series of plates were then incubated. Following incubation, the number of colonies on the plates was determined using a colony counter and used to calculate the number of organisms per gram for each class of gram positive bacteria, gram negative bacteria, yeast and mold.
- the salicylic acid/sorbic acid of Example 1 provided a stable preservative for the liposomes, even in the face of repeated challenges with bacteria, yeast, and mold spores.
- the phenonip preserved and Dowicil 200/methyl paraben/propyl paraben preserved liposomes failed to provide adequate protection from even one challenge.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne une composition cosmétique conservée comprenant des vésicules lipidiques ayant des lumières, lesdites lumières de vésicules lipidiques contenant une quantité efficace d'un point de vue cosmétique d'un ingrédient actif, une quantité efficace d'un point de vue conservation d'une combinaison d'acide sorbique et d'acide salicylique ou des sels solubles dans l'eau correspondants, une base en une quantité qui donne à une lumière de vésicule lipidique un pH compris entre environ 5 et environ 6, et de l'eau.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39041199A | 1999-09-03 | 1999-09-03 | |
US390411 | 1999-09-03 | ||
PCT/US2000/022985 WO2001017507A1 (fr) | 1999-09-03 | 2000-08-22 | Liposomes conserves |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1207854A1 true EP1207854A1 (fr) | 2002-05-29 |
Family
ID=23542376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00959298A Withdrawn EP1207854A1 (fr) | 1999-09-03 | 2000-08-22 | Liposomes conserves |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1207854A1 (fr) |
JP (1) | JP2003535030A (fr) |
WO (1) | WO2001017507A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006124300A (ja) * | 2004-10-27 | 2006-05-18 | Takasago Internatl Corp | ベシクル調製物 |
WO2013072929A2 (fr) * | 2011-09-23 | 2013-05-23 | Indian Institute Of Technology | Composition cosmétique à base d'articles nanoparticulaires |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4643939A (en) * | 1986-03-04 | 1987-02-17 | Shiseido Company Ltd. | Oil absorbing cosmetic tissue |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
FR2687314A1 (fr) * | 1992-02-18 | 1993-08-20 | Oreal | Dispersion de vesicules lipidiques, composition cosmetique et/ou pharmaceutique la contenant et procede de preparation de ladite dispersion. |
DK0616799T3 (da) * | 1993-03-24 | 2000-09-18 | Collaborative Lab Inc | Kosmetisk applikationssystem for salicylsyre og fremgangsmåde til fremstilling heraf |
-
2000
- 2000-08-22 JP JP2001521298A patent/JP2003535030A/ja active Pending
- 2000-08-22 WO PCT/US2000/022985 patent/WO2001017507A1/fr not_active Application Discontinuation
- 2000-08-22 EP EP00959298A patent/EP1207854A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0117507A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003535030A (ja) | 2003-11-25 |
WO2001017507A1 (fr) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1242095B1 (fr) | Compositions antimicrobiennes et procedes d'utilisation | |
AU2005201276B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
JP2958774B2 (ja) | アンホテリシンbリポソームの改良調整法 | |
EP0153364B1 (fr) | Amelioration de l'activite antimicrobienne par l'incorporation d'un melange d'agents antimicrobiens dans des vesicules de lipides | |
EP1386905B1 (fr) | Solution stable de coenzyme q reduite | |
US8232320B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
EP1041978A1 (fr) | Methodes d'inactivation de bacteries, y compris des spores bacteriennes | |
US20110091556A1 (en) | Antimicrobial compositions and methods of use | |
US20020045667A1 (en) | Non-toxic antimicrobial compositions and methods of use | |
US20110070306A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
KR101474577B1 (ko) | 미토콘드리아 기능의 향상을 위한 카디오리핀 포함 리포좀 | |
AU2002350587A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
JPH06279230A (ja) | サリチル酸賦与のための化粧品組成物とその製法 | |
CN101557803B (zh) | 用于改善线粒体功能的含有心磷脂的脂质体 | |
JPS63126820A (ja) | 外皮用リポソ−ム製剤 | |
EP1035837B1 (fr) | Compositions lipidiques et leur utilisation | |
EP1207854A1 (fr) | Liposomes conserves | |
WO2005030172A1 (fr) | Compositions antimicrobiennes en nanoemulsion et methodes associees | |
EP1360958A2 (fr) | Formulation liposomique de propionate de clobetasol | |
US6936273B2 (en) | Liposomal analgesic formulation and use | |
KR102189174B1 (ko) | 산업용 항균제 조성물 | |
BRPI0903009B1 (pt) | Vesículas lipídicas de carotenoides, composição, processo de preparação de vesículas lipídicas de carotenoides e uso de vesículas lipídicas de carotenoides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB |
|
18W | Application withdrawn |
Effective date: 20040414 |